Krystal Biotech (KRYS) Competitors

Krystal Biotech (NASDAQ:KRYS) and Inhibrx (NASDAQ:INBX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Is KRYS or INBX more profitable?

Krystal Biotech has a net margin of 0.00% compared to Inhibrx's net margin of -13,408.95%. Krystal Biotech's return on equity of -5.74% beat Inhibrx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	N/A	-5.74%	-5.45%
Inhibrx	-13,408.95%	-678.51%	-91.73%

Does the MarketBeat Community prefer KRYS or INBX?

Krystal Biotech received 247 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 66.83% of users gave Krystal Biotech an outperform vote while only 60.78% of users gave Inhibrx an outperform vote.

Company	Underperform	Outperform
Krystal Biotech	Outperform Votes 278 66.83%	Underperform Votes 138 33.17%
Inhibrx	Outperform Votes 31 60.78%	Underperform Votes 20 39.22%

Which has more volatility & risk, KRYS or INBX?

Krystal Biotech has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Inhibrx has a beta of 2.87, indicating that its share price is 187% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in KRYS or INBX?

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx shares are owned by institutional investors. 14.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 25.8% of Inhibrx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has preferable earnings & valuation, KRYS or INBX?

Krystal Biotech has higher revenue and earnings than Inhibrx. Inhibrx is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$50.70M	89.57	$10.93M	$1.87	85.03
Inhibrx	$1.80M	999.97	-$241.36M	-$5.03	-6.83

Do analysts prefer KRYS or INBX?

Krystal Biotech currently has a consensus price target of $177.63, suggesting a potential upside of 11.71%. Inhibrx has a consensus price target of $27.00, suggesting a potential downside of 21.40%. Given Krystal Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Krystal Biotech is more favorable than Inhibrx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Inhibrx	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the media refer more to KRYS or INBX?

In the previous week, Krystal Biotech had 2 more articles in the media than Inhibrx. MarketBeat recorded 7 mentions for Krystal Biotech and 5 mentions for Inhibrx. Krystal Biotech's average media sentiment score of 1.23 beat Inhibrx's score of 0.95 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats Inhibrx on 15 of the 18 factors compared between the two stocks.